查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1417528

氣喘和慢性阻塞性肺病治療藥物市場報告：至2030年的趨勢、預測和競爭分析

Asthma and COPD Drugs Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

氣喘和慢性阻塞性肺病治療藥物的趨勢和預測

至2030年，全球氣喘和慢性阻塞性肺病藥物市場預計將達到408億美元，2024年至2030年的年複合成長率為4.3%。該市場的主要驅動力是呼吸系統疾病治療方法的改進和新產品的推出、對標靶藥物和生技藥品的興趣增加以及都市化和人口老化的加劇。由於氣喘和慢性阻塞性肺病市場的機會，全球氣喘和慢性阻塞性肺病藥物市場的未來前景看好。

氣喘與慢性阻塞性肺病藥物市場洞察

Lucintel 預測，在預測期內，組合藥物仍將是最大的細分市場。

由於氣喘發病率不斷增加、製造業中重要參與者的存在、吸菸習慣以及該地區已建立的基礎設施，北美在預測期內仍將是最大的地區。

常見問題

Q1.市場規模有多大？

A1.到2030年，全球氣喘和慢性阻塞性肺病藥物市場預計將達到 408 億美元。

Q2.市場成長預測如何？

A2.2024年至2030年，全球氣喘和慢性阻塞性肺病藥物市場預計將以4.3%的年複合成長率成長。

Q3.影響市場成長的主要促進因素有哪些？

A3.該市場的主要驅動力是呼吸系統疾病治療方法的改進和新產品的推出、對標靶藥物和生技藥品的興趣增加以及都市化和人口老齡化的加劇。

Q4.市場的主要細分市場是什麼？

A4.全球氣喘和慢性阻塞性肺病藥物市場前景廣闊，氣喘和慢性阻塞性肺病市場充滿機會。

Q5.市場上主要企業有哪些？

A5.主要的氣喘和慢性阻塞性肺病治療藥物公司如下。

  • Novartis
  • Glaxosmithkline
  • Organon
  • Boehringer Ingelheim International
  • Abbott Laboratories
  • AstraZeneca
  • Sanofi
  • Hoffmann-La Roche
  • Vectura Group
  • Teva Pharmaceutical Industries

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預計組合藥物在預測期內仍將是其最大的細分市場。

Q7.未來五年預計哪個地區將成為最大的市場？

A7.由於氣喘發病率的增加、製造業重要參與者的存在、吸菸習慣以及該地區已建立的基礎設施，在預測期內，北美將繼續成為最大的地區。

Q8.可以客製化報告嗎？

A8.是的，Lucintel 提供 10%的客製化服務，無需額外付費。

目錄

第1章 執行摘要

第2章 全球氣喘與慢性阻塞性肺病藥物市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球氣喘和慢性阻塞性肺病治療藥物市場趨勢（2018-2023）和預測（2024-2030）
  • 依疾病分類的全球氣喘和慢性阻塞性肺病藥物市場
    • 氣喘
    • COPD
  • 依藥物類別分類的全球氣喘和慢性阻塞性肺病治療市場
    • 組合藥物
    • 短效BETA2促效劑
    • 長效BETA2促效劑
    • 白三烯拮抗劑
    • 抗膽鹼劑
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球氣喘和慢性阻塞性肺病藥物市場（依地區）
  • 北美氣喘與慢性阻塞性肺病藥物市場
  • 歐洲氣喘與慢性阻塞性肺病藥物市場
  • 亞太氣喘及慢性阻塞性肺病藥物市場
  • 其他地區氣喘及慢性阻塞性肺病藥物市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球氣喘和慢性阻塞性肺病藥物市場成長機會（依疾病）
    • 全球氣喘和慢性阻塞性肺病藥物市場成長機會（依藥物類別）
    • 全球氣喘和慢性阻塞性肺病藥物市場成長機會（依地區）
  • 全球氣喘和慢性阻塞性肺病藥物市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 全球氣喘和慢性阻塞性肺病藥物市場的產能擴張
    • 全球氣喘和慢性阻塞性肺病治療市場的合併、收購和合資企業
    • 認證和許可

第7章 主要企業概況

  • Novartis
  • Glaxosmithkline
  • Organon
  • Boehringer Ingelheim International
  • Abbott Laboratories
  • AstraZeneca
  • Sanofi
  • Hoffmann-La Roche
  • Vectura Group
  • Teva Pharmaceutical Industries
簡介目錄

Asthma and COPD Drugs Trends and Forecast

The future of the global asthma and COPD drugs market looks promising with opportunities in the asthma and COPD markets. The global asthma and COPD drugs market is expected to reach an estimated $40.8 billion by 2030 with a CAGR of 4.3% from 2024 to 2030. The major drivers for this market are improvements in treating respiratory conditions and the introduction of new products, rising interest in targeted medicines and biologics, as well as, urbanization and an aging population on the rise.

A more than 150-page report is developed to help in your business decisions.

Asthma and COPD Drugs by Segment

The study includes a forecast for the global asthma and COPD drugs by diseases, medication class, and region.

Asthma and COPD Drugs Market by Diseases [Shipment Analysis by Value from 2018 to 2030]:

  • Asthma
  • COPD

Asthma and COPD Drugs Market by Medication Class [Shipment Analysis by Value from 2018 to 2030]:

  • Combination Drugs
  • Short Acting Beta Agonists
  • Long Acting Beta Agonists
  • Leukotriene Antagonists
  • Anticholinergics
  • Others

Asthma and COPD Drugs Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Asthma and COPD Drugs Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies asthma and COPD drugs companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the asthma and COPD drugs companies profiled in this report include-

  • Novartis
  • Glaxosmithkline
  • Organon
  • Boehringer Ingelheim International
  • Abbott Laboratories
  • AstraZeneca
  • Sanofi
  • Hoffmann-La Roche
  • Vectura Group
  • Teva Pharmaceutical Industries

Asthma and COPD Drugs Market Insights

Lucintel forecasts that combination drug will remain the largest segment over the forecast period.

North America will remain the largest region over the forecast period due to the increased frequency of asthma, the presence of significant actors in manufacturing, the tobacco smoking habit, and the region's well-established infrastructure.

Features of the Global Asthma and COPD Drugs Market

Market Size Estimates: Asthma and COPD drugs market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Asthma and COPD drugs market size by diseases, medication class, and region in terms of value ($B).

Regional Analysis: Asthma and COPD drugs market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different diseases, medication class, and regions for the asthma and COPD drugs market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the asthma and COPD drugs market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the asthma and COPD drugs market size?

Answer: The global asthma and COPD drugs market is expected to reach an estimated $40.8 billion by 2030.

Q2. What is the growth forecast for asthma and COPD drugs market?

Answer: The global asthma and COPD drugs market is expected to grow with a CAGR of 4.3% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the asthma and COPD drugs market?

Answer: The major drivers for this market are improvements in treating respiratory conditions and the introduction of new products, rising interest in targeted medicines and biologics, as well as, urbanization and an aging population on the rise.

Q4. What are the major segments for asthma and COPD drugs market?

Answer: The future of the global asthma and COPD drugs market looks promising with opportunities in the asthma and COPD markets.

Q5. Who are the key asthma and COPD drugs market companies?

Answer: Some of the key asthma and COPD drugs companies are as follows.

  • Novartis
  • Glaxosmithkline
  • Organon
  • Boehringer Ingelheim International
  • Abbott Laboratories
  • AstraZeneca
  • Sanofi
  • Hoffmann-La Roche
  • Vectura Group
  • Teva Pharmaceutical Industries

Q6. Which asthma and COPD drugs market segment will be the largest in future?

Answer: Lucintel forecasts that combination drug will remain the largest segment over the forecast period.

Q7. In asthma and COPD drugs market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to the increased frequency of asthma, the presence of significant actors in manufacturing, the tobacco smoking habit, and the region's well-established infrastructure.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the asthma and COPD drugs market by diseases (asthma and COPD), medication class (combination drugs, short acting beta agonists, long acting beta agonists, leukotriene antagonists, anticholinergics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Asthma and COPD Drugs Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Asthma and COPD Drugs Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Asthma and COPD Drugs Market by Diseases
    • 3.3.1: Asthma
    • 3.3.2: COPD
  • 3.4: Global Asthma and COPD Drugs Market by Medication Class
    • 3.4.1: Combination Drugs
    • 3.4.2: Short Acting Beta Agonists
    • 3.4.3: Long Acting Beta Agonists
    • 3.4.4: Leukotriene Antagonists
    • 3.4.5: Anticholinergics
    • 3.4.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Asthma and COPD Drugs Market by Region
  • 4.2: North American Asthma and COPD Drugs Market
    • 4.2.2: North American Asthma and COPD Drugs Market by Medication Class: Combination Drugs, Short Acting Beta Agonists, Long Acting Beta Agonists, Leukotriene Antagonists, Anticholinergics, and Others
  • 4.3: European Asthma and COPD Drugs Market
    • 4.3.1: European Asthma and COPD Drugs Market by Diseases: Asthma and COPD
    • 4.3.2: European Asthma and COPD Drugs Market by Medication Class: Combination Drugs, Short Acting Beta Agonists, Long Acting Beta Agonists, Leukotriene Antagonists, Anticholinergics, and Others
  • 4.4: APAC Asthma and COPD Drugs Market
    • 4.4.1: APAC Asthma and COPD Drugs Market by Diseases: Asthma and COPD
    • 4.4.2: APAC Asthma and COPD Drugs Market by Medication Class: Combination Drugs, Short Acting Beta Agonists, Long Acting Beta Agonists, Leukotriene Antagonists, Anticholinergics, and Others
  • 4.5: ROW Asthma and COPD Drugs Market
    • 4.5.1: ROW Asthma and COPD Drugs Market by Diseases: Asthma and COPD
    • 4.5.2: ROW Asthma and COPD Drugs Market by Medication Class: Combination Drugs, Short Acting Beta Agonists, Long Acting Beta Agonists, Leukotriene Antagonists, Anticholinergics, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Asthma and COPD Drugs Market by Diseases
    • 6.1.2: Growth Opportunities for the Global Asthma and COPD Drugs Market by Medication Class
    • 6.1.3: Growth Opportunities for the Global Asthma and COPD Drugs Market by Region
  • 6.2: Emerging Trends in the Global Asthma and COPD Drugs Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Asthma and COPD Drugs Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Asthma and COPD Drugs Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Novartis
  • 7.2: Glaxosmithkline
  • 7.3: Organon
  • 7.4: Boehringer Ingelheim International
  • 7.5: Abbott Laboratories
  • 7.6: AstraZeneca
  • 7.7: Sanofi
  • 7.8: Hoffmann-La Roche
  • 7.9: Vectura Group
  • 7.10: Teva Pharmaceutical Industries